Portal de Periódicos da CAPES

Somatostatin: Newcomer from the Hypothalamus

1974; Massachusetts Medical Society; Volume: 290; Issue: 17 Linguagem: Inglês

10.1056/nejm197404252901711

1533-4406

Paul Brazeau, Roger Guillemin,

Neuroendocrine Tumor Research Advances

Several clinical groups in this country and in Europe have recently reported data obtained after the administration of synthetic somatostatin — the latest of the hypothalamic hypophysiotropic peptides.1 2 3 This issue of the Journal contains an elegant study by Yen and his collaborators on the striking effects of somatostatin in a series of patients with acromegaly. Somatostatin acutely and reversibly inhibits the secretion of pituitary growth hormone and of glucagon and insulin.What is somatostatin? How and when did it come about?Readers of the Journal are well aware of the concept establishing the hypothalamus as the modulator of the anterior . . .